

Pharmacotherapy in acute coronary syndromes


Perspective from first line and regional hospitals in Czech Republic

Petr Jansky

Pilot MI registry (n=3188)

6 non PCI hospitals


Discharge pharmacotherapy




CZECH registry

All ACS patients
11/2005
N 1921


1/ all PCI hospitals (80%)
2/ all community hospitals
in two regions (20%)



Discharge pharmacotherapy STEMI



Discharge pharmacotherapy nonSTE ACS



Recommendations for performance measures

- Development of regional and/or national programmes to systematically measure performance indicators and provide feedback to individual hospitals is strongly encouraged (I-C).

European Heart Journal, July 2007



- Confirmed acute coronary syndromes (STEMI, NONSTEMI, unstable AP)
- Continually since 1.7.2008
- 32 non cath hospitals


Quality of pharmacotherapy

- Prehospital phase
- Early hospital phase
- On discharge

Patient characteristics 7/2008-3/2010


n	% STEMI	% males	Mean age $\pm$ SD	
			males	females
3995	27,5	60,6	66,8 $\pm$ 12,4	74,2 $\pm$ 11,0

Prehospital pharmacotherapy







Prehospital pharmacotherapy EMS vs physician



Prehospital pharmacotherapy




Evidence-based medical therapy
(heparin, ASA, BB, statin, thienopyridin)
within the first 24 hours after admission
is associated with lower in-hospital mortality in NSTEMI



N 1889, $p < 0,001$

Monhart et al., ESC 2008


Aspirin



Linear trend: n.s.




Betablockers



Linear trend: n.s.




Clopidogrel



Linear trend: $p=0,023$




Statin



Linear trend: $p < 0,001$




LMWH



Linear trend: n.s.




Heparin



Linear trend: $p=0,036$



Fondaparinux




Linear trend: $p=0,011$

Pharmacotherapy within 24 hours after admission

%	Males	Females	≤70 y	>70 y	STEMI	NSTEMI
Aspirin	90,8	88,4	92,7	87,4***	92,9	89,7*
Clopidogrel	69,6	60,8**	74,2	58,9***	77,4	65,4***
Heparin	25,8	19,6*	28,2	19,1***	53,5	16,0***
LMWH	60,7	65,5	59,8	65,2	42,3	66,2***
BB	66,6	65,1	67,6	64,6*	52,1	67,7***
Fondaparinux	16,0	15,2	16,3	15,0	9,3	19,5***
ACEI	59,6	60,2	60,1	59,5	47,3	60,3***
Statin	66,6	64,1	70,2	61,6***	53,8	65,6***


* $p < 0,05$; ** $p < 0,01$; *** $p < 0,001$

Aspirin




Linear trend: n.s.

Clopidogrel




Linear trend: n.s.

Clopidogrel on discharge – individual hospitals




Betablockers




Linear trend: n.s.



Betablockers on discharge – individual hospitals




ACEI




Linear trend: $p=0,012$

Statin



Linear trend: $p < 0,001$

Combination (aspirin, clopidogrel, BB, ACEI, statin)



Linear trend: $p=0,010$

Discharge pharmacotherapy

%	Males	Females	≤ 70 y	> 70 y	STEMI	NSTEMI
Aspirin	93,5	91,6	95,6	89,9***	96,6	92,5***
Clopidogrel	74,2	62,9***	78,5	60,9***	87,3	71,6***
BB	85,2	83,4	86,0	83,0*	86,1	84,0
ACEI	79,8	77,6	79,9	78,1	82,3	77,0**
Statin	89,7	85,4	92,3	83,6***	91,4	85,7**

* $p < 0,05$; ** $p < 0,01$; *** $p < 0,001$

Conclusion

- Unsatisfactory prehospital pharmacotherapy
- In-hospital pharmacotherapy is relatively good (exc. elderly, females, NONSTEMI)
- Interhospital variability in the quality of care
- Improvement in some recommended therapies (statins, clopidogrel in the acute phase) over short time period

Thank you for your attention !